agio

(redirected from agios)
Also found in: Dictionary, Thesaurus, Financial, Encyclopedia, Wikipedia.
See: brokerage

AGIO, aggio. This term is used to denote the difference of price between the value of bank notes and nominal money, and the coin of the country. Encyc.

Mentioned in ?
References in periodicals archive ?
A firefighting vessel extinguished the blaze on 22-meter Arion before it was tugged to Agios Nikolaos, the port authority said.
Apart from delivering financial benefits to Agios, Penn and the Abramson Family Cancer Research Institute, it would also be beneficial to cancer patients.
Agios has multiple first-in-class programs in cancer metabolism and inborn errors of metabolism advancing toward the clinic, in addition to an active research and discovery pipeline across both therapeutic areas.
In the article, Agios scientists reported the first inhibitors of mutant IDH1 that show good potency in a glioblastoma cell line harboring IDH1 mutation and achieve robust tumor 2-HG inhibition in the tumor xenograft model.
We congratulate Agios, BIND, Oasys and Selecta for being recognized on this global stage and are looking forward to their continued success.
This publication arises from collaborative work conducted between Agios scientists and colleagues at the California Institute of Technology and the Genomics Institute of the Novartis Research Foundation.
The strength of our science and success of our efforts to date are a direct result of the amazing people at Agios," said Duncan Higgons, chief operating officer of Agios.
Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in cancer metabolism, announced today the publication of a new study that provides further evidence of the link between a mutated metabolic enzyme and acute myeloid leukemia (AML), one of the most common types of leukemia in adults.
To support and drive these efforts, Agios has built a robust platform integrating cancer biology, metabolomics, biochemistry and informatics to enable target and biomarker identification.
Due to the rapid success and progression of our pipeline and platform, Agios has experienced a need for significant resource assistance.
ChemPartner) a wholly owned subsidiary of ShangPharma Corporation, today announced that ChemPartner scientists are pleased to have been involved in recent groundbreaking cancer research from Agios Pharmaceuticals through the companies' ongoing partnership.